TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11518072
Drug: Ketanserin (5‐HT2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (5‐HT2 receptor antagonist)
Study: 11518072
Drug: WAY‐100635 (5‐HT1A
Approvals — FDA: no, EMA: no, PMDA: no
Description: WAY‐100635 (5‐HT1A antagonist)
Study: 7841729
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of racemic adrenaline
Study: 2905636
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg glafenine
Study: 23840296
Drug: Sodium Ferulate
Normalized name: ferulate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Ferulate (SF) pretreatment for 14 days with bupropion (150 mg)
Study: 14643034
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg oral misoprostol
Study: 9024268
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg 17-beta-estradiol orally for 3 months (with 1 mg norethisterone acetate added for 10 days during the last 16 days for endometrial protection)
Study: 3305221
Drug: Myelosuppressive postinduction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myelosuppressive postinduction treatment
Study: 3305221
Drug: Monthly maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly maintenance chemotherapy
Study: 3305221
Drug: Intensive two-course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive two-course preremission therapy
Study: 26699899
Drug: Atorvastatin (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (initial dose of 40 mg at admission followed by 10 mg/day for 30 days)
Study: 21916603
Drug: Low vitamin
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low vitamin D status (serum 25-hydroxyvitamin D < 32 ng/mL)
Study: 8417634
Drug: Glipizide 20
Normalized name: Glipizide
DrugBank: Glipizide (DB01067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glipizide 20 mg
Study: 8417634
Drug: Glipizide 40
Normalized name: Glipizide
DrugBank: Glipizide (DB01067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glipizide 40 mg
Study: 3777463
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic solution with hyaluronidase (75 international units diluted in 5 ml of local anesthetic mixture)
Study: 3777463
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic solution without hyaluronidase
Study: 29558953
Drug: Gum Arabic
Normalized name: Gum arabic
DrugBank: Acacia (DB10451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gum Arabic (30 g daily for 3 months)
Study: 29558953
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 g daily for 3 months)
Study: 25066102
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavior therapy (ICBT) with booster program
Study: 25066102
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavior therapy (ICBT) without booster program
Study: 20084409
Drug: Caudal blockade
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal blockade with 0.5% bupivacaine [10 ml x height (m)]
Study: 19453397
Drug: FluBlok, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: FluBlok, a recombinant trivalent hemagglutinin vaccine
Study: 19453397
Drug: Traditional egg-based
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional egg-based trivalent inactivated influenza vaccine (TIV)
Study: 15935019
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate 200 mg
Study: 8676421
Drug: VO2I >
Approvals — FDA: no, EMA: no, PMDA: no
Description: VO2I > or = 150 or DO2I > or = 600 mL/min/m2 (Group 1)
Study: 1804599
Drug: Ceftriaxone 2
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 2 g once daily + Amikacin 0.5 g
Study: 1804599
Drug: Ceftazidime 2
Normalized name: ceftazidime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 2 g twice daily + Amikacin 0.5 g b.i.d.
Study: 6097173
Drug: 2.0 g
Normalized name: Fifty50 2.0 Glucose Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g of sulbactam given in a single intramuscular dose with 1.0 g of probenecid orally
Study: 6097173
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g of intramuscular sulbactam given twice, 4 h apart
Study: 18525042
Drug: Hypothermia therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermia therapy (32.5 degrees C for 24 hours)
Study: 7085368
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics (cefazolin or carbenicillin, three perioperative doses)
Study: 23394404
Drug: Drug-eluting balloon
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting balloon (Sequent please; B. Braun) followed by bare metal stent (Coroflex Blue; B. Braun)
Study: 23394404
Drug: Drug-eluting stent
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stent (Resolute Integrity; Boston Scientific)
Study: 21247998
Drug: ondansetron (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron (4 μg/kg twice daily)
Study: 11593458
Drug: Videotape preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Videotape preparation before hip replacement surgery
Study: 11593458
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no videotape preparation)
Study: 11593458
Drug: Videotape preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Videotape preparation
Study: 125133
Drug: Methandienone 10
Normalized name: Metandienone
DrugBank: Metandienone (DB13586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methandienone 10 mg/day
Study: 125133
Drug: Methandienone 25
Normalized name: Metandienone
DrugBank: Metandienone (DB13586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methandienone 25 mg/day
Study: 28286189
Drug: Dried aqueous
Normalized name: peptone,dried
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dried aqueous spearmint extract (600 mg/day) for 90 days
Study: 28286189
Drug: Dried aqueous
Normalized name: peptone,dried
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dried aqueous spearmint extract (900 mg/day) for 90 days
Study: 17538539
Drug: 1.6 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 g/day of plant sterols (PS) for 3 weeks
Study: 17538539
Drug: 3.0 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 g/day of plant sterols (PS) for 3 weeks
Study: 17511685
Drug: Steroid (methylprednisolon)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Steroid (methylprednisolon)
Study: 11688766
Drug: Nifedipine gastrointestinal
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine gastrointestinal therapeutic system (NI) 30-60 mg once a day
Study: 11688766
Drug: Amlodipine (AM)
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine (AM) 5-10 mg once a day
Study: 7837683
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor (omeprazole 20mg once daily)
Study: 7837683
Drug: H2-blocker (famotidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-blocker (famotidine 20mg twice daily)
Study: 3045781
Drug: Dicloxacillin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dicloxacillin (25 mg/kg/day for 10 days)
Study: 24912561
Drug: Rehabilitation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation treatment which did not include training of sensory strategies
Study: 20509752
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg b.i.d. + Amoxicillin 1000 mg + Clarithromycin 500 mg for 1 week followed by placebo for 3 weeks
Study: 20509752
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg b.i.d. + Placebo antibiotics for 1 week followed by Esomeprazole 20 mg o.d. for 3 weeks
Study: 20509752
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg o.d. after initial treatment
Study: 16035144
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 45 mg
Study: 12236071
Drug: Sustained-release sparfloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release sparfloxacin chip (SRS chip)
Study: 7669991
Drug: Tetrahydroaminoacridine 75
Normalized name: Tetrahydroaminoacridine
DrugBank: Tacrine (DB00382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetrahydroaminoacridine 75 mg
Study: 7669991
Drug: Tetrahydroaminoacridine 25
Normalized name: Tetrahydroaminoacridine
DrugBank: Tacrine (DB00382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetrahydroaminoacridine 25 mg
Study: 1823750
Drug: Hydrochlorothiazide, 25
Normalized name: HydroCHLOROthiazide, 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide, 25 mg/day
Study: 7193918
Drug: i.v. DDAVP
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. DDAVP (0.1‐0.4 μg/Kg)
Study: 7193918
Drug: i.n. DDAVP
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.n. DDAVP (1‐4 μg/Kg)
Study: 7193918
Drug: i.v. DDAVP
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. DDAVP (0.4 μg/Kg) single dose
Study: 7193918
Drug: i.v. DDAVP
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. DDAVP (0.4 μg/Kg) repeated doses
Study: 28684276
Drug: Capsaicin (100µg/50µl)
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin (100µg/50µl) administered into ST36 or ST37 acupoint
Study: 28684276
Drug: Capsaicin administered
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin administered into ST36 acupoint
Study: 28684276
Drug: Pre-emptive treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-emptive treatment of contralateral ST36 acupoint with 43°C heating-needle stimulation
Study: 28684276
Drug: Non-acupoint area
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-acupoint area treatment
Study: 25976567
Drug: S-line blood-liquid
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-line blood-liquid warmer with Mediset infusion set
Study: 12008788
Drug: Pleconaril 400
Normalized name: pleconaril
DrugBank: Pleconaril (DB05105)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pleconaril 400 mg three-times daily for 7 days
Study: 12008788
Drug: Pleconaril 400
Normalized name: pleconaril
DrugBank: Pleconaril (DB05105)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pleconaril 400 mg three-times daily
Study: 2569485
Drug: 650 mg
Normalized name: bran 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg acetaminophen plus 60 mg phenyltoloxamine citrate
Study: 2569485
Drug: 650 mg
Normalized name: bran 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg acetaminophen alone
Study: 28644243
Drug: No‐MASK +
Approvals — FDA: no, EMA: no, PMDA: no
Description: No‐MASK + O2 (10 l/min of oxygen via nasal cannula)
Study: 27039086
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (10 sessions of real acupuncture)
Study: 17323786
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg nebivolol PO (n = 10)
Study: 17323786
Drug: metoprolol tartrate
Normalized name: Metoprolol Tartrate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: metoprolol tartrate 50 mg PO (n = 10)
Study: 15481851
Drug: Lanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanthanum carbonate 1,350 mg/day
Study: 15481851
Drug: Lanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanthanum carbonate 2,250 mg/day
Study: 15481851
Drug: Lanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanthanum carbonate (all doses)
Study: 11479411
Drug: Oral inoculation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral inoculation with 106 viable cells of plasmid-free human E. coli within 2 hours after birth
Study: 11479411
Drug: Oral inoculation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral inoculation with 106 viable cells of plasmid-free human E. coli
Study: 3262598
Drug: Ascorbate (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascorbate (3 grams daily for 14 days)
Study: 28961848
Drug: Dacarbazine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacarbazine (1000 mg/m2 every 3 weeks)
Study: 23081873
Drug: Single-dose systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose systemic methotrexate (MTX)
Study: 19049696
Drug: Emtricitabine/Tenofovir DF
Normalized name: COBICISTAT/ELVITEGRAVIR/EMTRICITABINE/TENOFOVIR DF TAB,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emtricitabine/Tenofovir DF (200/300 mg q.d.)
Study: 19049696
Drug: Tacrolimus (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus (0.1 mg/kg/day)
Study: 19049696
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Emtricitabine/Tenofovir DF and Tacrolimus
Study: 16971718
Drug: Preoperative radiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiotherapy and postoperative chemotherapy
Study: 16971718
Drug: Preoperative chemoradiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemoradiotherapy and postoperative chemotherapy
Study: 16971718
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy adherence
Study: 16971718
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy adherence
Study: 10025903
Drug: VIM3ARAC regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIM3ARAC regimen (teniposide, ifosfamide, mitoxantrone, mitoguazone, high-dose methotrexate, high-dose cytarabine, prednisolone)
Study: 10025903
Drug: Overall survival
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall survival after treatment
Study: 10025903
Drug: Relapse off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relapse off therapy and performance status <2 at relapse
Study: 8749083
Drug: Lateral acceleration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral acceleration steps of 0.05 g, 0.1 g, 0.24 g of 600 ms duration
Study: 2375136
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg QS liquid
Study: 2375136
Drug: two 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: two 200 mg QS tablets
Study: 2375136
Drug: 550 mg
Normalized name: xylitol 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 550 mg QP liquid
Study: 2375136
Drug: two 275
Approvals — FDA: no, EMA: no, PMDA: no
Description: two 275 mg QP tablets
Study: 28314093
Drug: Pharmacogenetic (PGx)‐guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacogenetic (PGx)‐guided treatment
Study: 18937820
Drug: Mild laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild laser treatment
Study: 23793205
Drug: Essential oil
Normalized name: Essential oil
DrugBank: Rosemary oil (DB14689)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential oil of Cymbopogon citratus at 1.25 μL/mL concentration, applied three times a week as shampoo and twice a day as cream for 40 days.
Study: 23793205
Drug: 2% ketoconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% ketoconazole formulations, applied as control for 40 days.
Study: 16902744
Drug: Heavyweight PP
Normalized name: propoxyphene hydrochloride Oral Capsule [PP-Cap]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavyweight PP mesh (Prolene 10 x 15 cm, 1.5 g, group I, n = 232)
Study: 16902744
Drug: Mixed PP-
Normalized name: propoxyphene hydrochloride Oral Capsule [PP-Cap]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed PP- and Polyglactin mesh (Vypro II, 10 x 15 cm, 0.53 g, group II, n = 217)
Study: 16902744
Drug: Light-weight titanized
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light-weight titanized PP mesh (Ti-Mesh, 10 x 15 cm, 0.24 g, group III, n = 223)
Study: 8677083
Drug: Control (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (weekly pelvic examinations only)
Study: 28001016
Drug: Dapagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (10 mg) before breakfast for 90 days
Study: 24714415
Drug: AST‐120 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: AST‐120 plus once‐monthly administration of continuous EPO receptor activator (CERA)
Study: 20369705
Drug: Qianlie Jiedu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qianlie Jiedu Capsule + Rufloxacin
Study: 19080291
Drug: Failed early
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Failed early aspiration (volume of first daily aspirated secretions ≤ 20 ml)
Study: 11826413
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy (propranolol + isosorbide‐5‐mononitrate)
Study: 10463324
Drug: Zolmitriptan (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan (5 mg orally)
Study: 10463324
Drug: Ketanserin (5-HT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (5-HT receptor antagonist)
Study: 7547098
Drug: Tenidap sodium
Normalized name: tenidap sodium
DrugBank: Tenidap (DB13481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenidap sodium 40 mg
Study: 7022736
Drug: Atropine sulphate
Normalized name: Atropine sulphate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulphate (4 mg)
Study: 7022736
Drug: Atropine methonitrate
Normalized name: Atropine methonitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine methonitrate (2 mg)
Study: 7022736
Drug: Fenoterol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (400 μg)
Study: 7022736
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of atropine methonitrate with fenoterol
Study: 7022736
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of atropine sulphate with fenoterol
Study: 29781725
Drug: Expanded cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expanded cognitive stimulation therapy (CST) model combined with tai chi, 14 sessions, twice a week
Study: 29781725
Drug: Waitlist control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist control group received treatment as usual initially and expanded CST model later
Study: 23064538
Drug: HIV, HSV‐2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV, HSV‐2, and treponemal antibodies detected
Study: 18575162
Drug: Intrathecal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal administration of 0.1 mg morphine, 0.015 mg fentanyl and 15 mg hyperbaric bupivacaine (Group I, n = 20)
Study: 18575162
Drug: Psoas compartment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psoas compartment block with ropivacaine 0.475% 25 mL (Group II, n = 20)
Study: 18575162
Drug: Intrathecal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal administration of 0.1 mg morphine, 0.015 mg fentanyl and 15 mg hyperbaric bupivacaine (Group I)
Study: 12616845
Drug: National registry
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: National registry for drug-induced QT prolongation
Study: 10561636
Drug: 50‐g glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50‐g glucose beverage
Study: 10561636
Drug: 28 jelly
Normalized name: Ophthalmic Jelly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 jelly beans (50 g simple carbohydrate)
Study: 8916999
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 400 mg, 12 h prior to surgery
Study: 8916999
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol 800 mg, 2 to 4 hours prior to surgery
Study: 1863010
Drug: dipyridamole 75
Normalized name: dipyridamole 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: dipyridamole 75 mg three times daily and aspirin 330 mg once daily
Study: 1863010
Drug: physical exercise
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: physical exercise and dipyridamole 75 mg three times daily and aspirin 330 mg once daily
Study: 17095617
Drug: New agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: New agents for the treatment of acute leukemia
Study: 15143375
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch therapy, education and motivation
Study: 1299499
Drug: 40 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg.kg‐1 L‐ornithine.HCl
Study: 1299499
Drug: 100 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg.kg‐1 L‐ornithine.HCl
Study: 1299499
Drug: 170 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 170 mg.kg‐1 L‐ornithine.HCl
Study: 6744203
Drug: Chemotherapy (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (6 cycles of Adriamycin (45 mg/m2), vincristine (1.2 mg/m2), and cyclophosphamide (200 mg/m2 for 5 days) every 4 weeks)
Study: 6744203
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (radiotherapy and chemotherapy)